European Journal of Heart Failure

Papers
(The H4-Index of European Journal of Heart Failure is 54. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Abstract383
Adrenomedullin as a Marker of Hypoxia, Not Hypoperfusion. Letter Regarding the Article ‘Biologically Active Adrenomedullin as a Marker for Residual Congestion and Early Rehospitalization in Patients H220
Issue Information172
Machine learning to reveal hidden HFpEF: promise, pitfalls, and next steps155
Risk factors for the development of heart failure in patients with or without prior myocardial infarction144
139
Issue Information132
Tafamidis in Patients with Severe Heart Failure due to Transthyretin Amyloidosis Cardiomyopathy: Improved Long-Term Survival125
Rationale and Design of the ESC Heart Failure III Registry – Implementation and Discovery115
Effect of Dapagliflozin on Health Status and Quality of Life Across the Spectrum of Ejection Fraction: Participant-Level Pooled Analysis from the DAPA-HF and DELIVER Trials111
Association Between Liver Fibrosis, Plasma Volume Status, and Cardiovascular Mortality: The Hiroshima Study on Glucose Metabolism and Cardiovascular Diseases93
Clonal hematopoiesis is linked to increased risks of all-cause mortality, cardiovascular death, and bleeding complications in patients with atrial fibrillation92
Exercise Catheterization in Adults Post-Fontan with Normal and Abnormal Haemodynamic Criteria: Insights Into Normal Fontan Physiology90
Effect of Sacubitril/Valsartan in Heart Failure with Preserved Ejection Fraction Across the Age Spectrum in PARAGON-HF83
Percutaneous Repair of Moderate-to-Severe or Severe Functional Mitral Regurgitation in Patients with Symptomatic Heart Failure: Baseline Characteristics of Patients in the RESHAPE-HF2 Trial and Compar83
Decongestion Strategies In Patients Presenting with Acutely Decompensated Heart Failure: A Worldwide Survey Among Physicians80
Time-Varying Analyses of Survival and Outcomes in Patients with HeartMate 3 Left Ventricular Assist Devices79
Heart failure in pregnancy: where the 2025 ESC Guidelines ‘cardiovascular disease and pregnancy’ illuminate—and where shadows remain78
Exercise cardiac magnetic resonance biventricular volumetric reserve in heart failure with preserved ejection fraction76
Subclinical atrial fibrillation and the risk of heart failure: insights from ARTESiA74
Finerenone, Chronic Obstructive Pulmonary Disease, and Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial73
Letter regarding the article ‘Clinical profiles and prognostic impact of residual intravascular and tissue congestion in acute heart failure’72
Identifying Reliable Biomarkers for Pulmonary Congestion: Toward a Close Yet Sustainable Heart Failure Follow-Up70
Striving for the ‘Perfect’ Definition of Iron Deficiency in Heart Failure70
Similarities and Distinctions Between Acetazolamide and Sodium–Glucose Cotransporter 2 Inhibitors in Patients with Acute Heart Failure: Key Insights Into ADVOR and EMPULSE69
Reply to the letter regarding the article ‘Are mechanical circulatory supports the forgotten aspect in the implementation of therapies for heart failure?’68
Culture, Ethnicity, and Socio-Economic Status as Determinants of the Management of Patients with Advanced Heart Failure who Need Palliative Care: A Clinical Consensus Statement from the Heart Failure 67
Characteristics and Outcomes of Patients with a History of Cancer Recruited to Heart Failure Trials66
Issue Information66
Dissecting the Heart Failure Phenotype Through Phenomics66
Applying the ‘Touch-and-Go’ Concept to Mineralocorticoid Receptor Antagonists: A Paradigm Shift in Routine Heart Failure Management66
Cardiovascular Magnetic Resonance-Estimated Pulmonary Capillary Wedge Pressure, Congestion Markers, and Effect of Empagliflozin in Patients with Heart Failure with Reduced Ejection Fraction and Dysgly65
Letter Regarding the Article ‘Employment of Artificial Intelligence for an Unbiased Evaluation Regarding the Recovery of Right Ventricular Function After Mitral Valve Transcatheter Edge-To-Edge Repair65
Abstract65
Left ventricular volume and maximal functional capacity in heart failure with preserved ejection fraction: Size matters63
Expanding the Horizon of Medication Adherence Strategies in Acutely Decompensated Heart Failure. Letter Regarding the Article ‘Medication Adherence in Patients with Acutely Decompensated Heart Failure63
Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial62
Reply to ‘Morphine use in acute cardiogenic pulmonary oedema: is MIMO trial enough to change practice?’62
Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR Trial61
Improved Outcome up to Ten Years after Intravenous Immunoglobulin Therapy in Patients with Dilated Cardiomyopathy61
Incidence and Predictors of Weaning Failure From Veno-Arterial Extracorporeal Membrane Oxygenation Therapy in Patients With Cardiogenic Shock61
Response to Letter EURJHF-25-145559
Burst Steroid Therapy for Acute Heart Failure: The CORTAHF Randomized, Open-Label, Pilot Trial59
Salt Repletion and Diuretic Response: The Role of Serum Chloride. A Post-hoc Analysis of the SALT-HF Trial on Furosemide and Hypertonic Saline Solution Administration in Ambulatory Patients with Worse59
Determinants of Submaximal Exercise Intolerance in Patients with Heart Failure and Preserved Ejection Fraction: Insights from the Lactate Threshold58
Atrial Cardiomyopathy: From Healthy Atria to Atrial Failure. A Clinical Consensus Statement of the Heart Failure Association of the ESC58
Are Left Ventricular Ejection Fraction Phenotypes Meaningful in Acute Heart Failure?56
Clinical Profiles and Prognostic Impact of Residual Intravascular and Tissue Congestion in Acute Heart Failure56
Corrigendum to ‘Congestion in Heart Failure: A Circulating Biomarker-Based Perspective’ and Articles Listed Below56
Sacubitril/Valsartan Versus Enalapril in Chronic Chagas Cardiomyopathy with Heart Failure: Baseline Characteristics of the PARACHUTE-HF Trial55
Finerenone According to Insulin Resistance in Heart Failure: Insights from the FINEARTS-HF Trial55
Weight Change and Clinical Outcomes in Heart Failure with Reduced Ejection Fraction: Insights from EMPEROR-Reduced55
Predicting Survival in Patients with Severe Heart Failure: Risk Score Validation in the HELP-HF Cohort54
Effect of the cardiac myosin activator omecamtiv mecarbil on ventricular arrhythmias, cardiac arrest, and sudden death in heart failure with reduced ejection fraction: the GALACTIC-HF trial54
404-Error “Disease Not Found”: Unleashing the Translational Potential of -Omics Approaches Beyond Traditional Disease Classification in Heart Failure Research54
1.0688819885254